FindTrial
Sign In

FACTOR Xa INHIBITORS FOR VENOUS THROMBOEMBOLISM MANAGEMENT IN PATIENT WITH CANCER: A META-ANALYSIS

FACTOR Xa INHIBITORS FOR VENOUS THROMBOEMBOLISM MANAGEMENT IN PATIENT WITH CANCER - FACTOR Xa INHIBITORS FOR VTE MANAGEMENT IN CANCER: A META-ANALYSIS

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000040346
Enrollment
5
Registered
2020-06-12
Start date
2020-04-24
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In Cancer patients with VTE or risk of VTE

Interventions

None listed

Sponsors

Dr. Soetomo General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: any randomised controlled trials in which patients with a history of cancer or active cancer were allocated to receive an oral factor Xa inhibitor in one arm of treatment for the either treatment or prophylaxis of VTE

Exclusion criteria

Exclusion criteria: All phase II trials, trials involving anti-platelet in control arm of treatment, trials using anticoagulant as post-procedure prophylaxis of VTE

Design outcomes

Primary

MeasureTime frame
the recurrent VTE or VTE events rates and major bleeding incidence—

Countries

Asia(except Japan)

Contacts

Public ContactJohanes Nugroho

Department of Cardiology and Vascular Medicine, Faculty of Medicine Universitas Airlangga, Dr. Soeto Department of Cardiology and Vascular Medicine

j.nugroho.eko@fk.unair.ac.id+6282139090953

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026